Abstract
Chronic exposure to mild unpredictable stress (CMS) has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions. In the present study, in addition to confirming these behavioural observations, the binding properties of cortical beta-adrenergic and 5HT2 receptors, and hippocampal 5HT1A receptors were studied (using the ligands [3H]-dihydroalprenolol, [3H]-ketanserin and [3H]-8-OH-DPAT, respectively), following 7 weeks of CMS and 4 weeks of imipramine treatment (10mg/kg per day). CMS increased Bmax for all three receptor systems. Impramine decreased Bmax, reversing the effect of CMS, for beta-adrenergic and 5HT2 receptor binding, but increased Bmax for 5HT1A receptor binding. KDs were unaffected by either treatment. The beta-receptor and 5HT2 receptor binding data are consistent with accounts of antidepressant action derived from studies in normal animals, but the 5HT1A receptor binding data are more difficult to reconcile. In no case was there a good correlation between receptor binding and behavioural data.
Similar content being viewed by others
References
Akiyoshi J, Nagayama H, Tsuchiyama K (1988) Increase in the Bmax of 5-HT-1A receptor following chronic administration of mianserin in an animal model of depression. Jpn J Pschiatr Neurol 42:864–865
Akiyoshi J, Tsuchiyama K, Yamada K, Mizobe Y, Makamura M, Nagayama H (1992) Effect of IAP and chronic antidepressant administration on the 5HT1A receptor in rat cortical membranes. Prog Neuropsychopharmacol Biol Psychiatry 16:339–349
American Psychiatric Association (1987) DSM III R-diagnostic and statistical manual of psychiatric disorders, 3rd edition, revised. APA, Washington DC
Amsterdam JD (1992) Gepirone, a selective serotonin (5HT1A) partial agonist in the treatment of major depression. Prog Neuropsychopharmacol Biol Psychiatry 16:271–280
Amsterdam JD, Berwish N, Potter L, Rickels K (1987) Open trial of gepirone in the treatment of major depressive disorder. Curr Ther Res 41:185–193
Arango V, Ernsberger P, Marzuk PM, Chen J-S, Tierney H, Stanley M, Reis DJ, Mann JJ (1990) Autoradiographic demonstration of increased serotonin 5HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims. Arch Gen Psychiatr 47:1038–1047
Arora RC, Meltzer HY (1989) Serotonergic measures in the brains of suicide victims: 5HT2 binding sites in the frontal cortex of suicide victims and control subjects. Am J Psychiatry 146:730–736
Banerjee SP, Kung LS, Riggi SJ, Chanda SK (1977) Development of beta-adrenergic subsensitivity by antidepressants. Nature 268:455–456
Biegon A, Israeli M (1988) Regionally selective increases in beta-adrenegic receptor density in brains of suicide victims. Brain Res 442:199–203
Blackshear MA, Sanders-Bush E (1982) Serotonin receptor sensitivity after acute and chronic treatment with mianserin. J Pharmacol Exp Ther 221:303–308
Cheeta S, Broekkamp CLE, Willner P (1992) Reversal of stress-induced anhedonia by mianserin and its (+)-enantiomer. J Psychopharmacol 6, Abstr, 55
Cheetham SC, Crompton MR, Katona CLE, Horton RW (1988) Brain 5HT2 receptor binding sites in suicide victims. Brain Res 443:272–280
Deakin JFW, Graeff FG (1991) 5-HT and mechanisms of defence. J Psychopharmacol 5:305–315
Deakin JFW, Pennell I, Upadhyaya AK, Lofthouse R (1990) A neuroendocrine study of 5HT function in depression: Evidence for biological mechanisms of endogenous and psychosocial causation. Psychopharmacology 4:357–360
D'haenen H, Bossuyt A, Mertens J, Bossuyt-Piron C, Gijsemans M, Kaufman L (1992) SPECT imaging of serotonin2 receptors in depression. Psychiatr Res Neuroimaging 45:227–237
de Parmentier F, Cheetham SC, Crompton MR, Katona CL (1990) Brain beta-adrenoceptor binding sites in antidepressant-free depressed suicide victims. Brain Res 525:71–77
de Parmentier F, Cheetham SC, Crompton MR, Katona CL (1991) Brain beta-adrenoceptor binding sites in depressed suicide victims: Effects of antidepressant treatment. Psychopharmacology 105:283–288
Fabre LF (1990) Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychopharmacol 10:775–853
Garattini S, Bizzi A, Caccia S, Mennini T, Samanin R (1988) Progress in assessing the role of serotonin in the control of food intake. Clin. Neuropharmacol. 11 [Suppl. 1]:S8-S32
Goodwin GM, Green AR, Johnson P (1984) 5HT2 receptor characteristics in frontal cortex and 5HT2 receptor-mediated head-twitch behaviour following antidepressant treatment to mice. Br J Pharmacol 83:235–242
Hamon M, Emerit MB, El Mestikawy S, Verge D, Daval G, Marquet A, Gozlan H (1987) Pharmacological, biochemical and functional properties of 5-HT1A receptor binding sites labelled by [3H]-8-OH-DPAT in the rat brain. In: Dourish CT, Ahlenius S, Hutson PH (eds) Brain 5HT1A receptors. Ellis Horwood, Chichester, pp 34–51
Jenkins SW, Robinson DS, Fabre LF, Andary JJ, Messina ME, Reich LA (1990) Gepirone in the treatment of major depression. J Clin Psychopharmacol 10:775–853
Lesch KP (1991) 5-HT1A receptor responsivity in anxiety disorders and depression. Prog Neuropsychopharmacol Biol Psychiatry 15:723–733
Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM (1982) [3]-Ketanserin (R 41 486), a selective3H-ligand for serotonin2 receptor binding sites. Mol Pharmacol 21:301–314
Lund A, Mjellem-Joly N, Hole K (1992) Desipramine, administered chronically, influences 5-hydroxytryptamine1A-receptors, as measured by behavioural tests and receptor binding in rats. Neuropharmacology 31:25–32
Mann JJ, Stanley M, McBride PA, McEwen BS (1986) Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 43:954–959
McKeith IG, Marshall EF, Ferrier IN, Armstrong MM, Kennedy WN, Perry RH, Perry EK, Eccleston D (1987) 5HT receptor binding in post-mortem brain from patients with affective disorder. J Affect Dis 13:67–74
Mizuta T, Segawa T (1988) Chronic effects of imipramine and lithium on postsynaptic 5-HT1A and 5-HT1B and on presynaptic 5-HT3 sites in rat brain. Jpn J Pharmacol 47:107–113
Mogilnicka E, Wedzony K, Klimek V, Nowak G (1985) The importance of timing for the action of alpha1- or beta-agonists: possible relationship with the density of [3H]-prazosin and [3H]-dihydroalprenolol binding sites. Eur. J Pharmacol 113:279–282
Moreau JL, Jenck F, Martin JR, Mortas P, Haefely WE (1992) Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmental self-stimulation behavior in rats. Eur Neuropsychopharmacol 2:43–49
Moreau JL, Jenck F, Martin JR, Mortas P, Haefely WE (1993) Effects of moclobemide, a new generation reversible MAO-A inhibitor, in a novel animal model of depression. Pharmacopsychiatry (in press)
Muscat R, Willner P (1992) Suppression of sucrose drinking by chronic mild unpredictable stress. A methodological analysis. Neurosci Biobehav Rev 16:507–517
Muscat R, Towell A, Willner P (1988) Changes in dopamine autoreceptor sensitivity in an animal model of depression. Psychopharmacology 94:545–550
Muscat R, Sampson D, Willner P (1990) Dopaminergic mechanism of imipramine action in an animal model of depression. Biol Psychiatry 28:223–230
Muscat R, Papp M, Willner P (1992) Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology 109:433–438
Odagaki Y, Koyama T, Yamachita I (1991) No alterations in the 5HT1A-mediated inhibition of forskolin-stimulated adenylate cyclase activity in the hippocampal membranes from rats chronically treated with lithium or antidepressants. J Neural Transm 86:85–96
Owen F, Cross AJ, Crow TJ, Deakin JFW, Ferrier IN, Lofthouse R, Poulter M (1983) Brain 5HT2 receptors and suicide. Lancet II:1256
Newman ME, Drumer D, Lere B (1990) Single and combined effects of desipramine and lithium on serotonergic receptor number and second messenger function in rat brain. J Pharmacol Exp Ther 252:826–831
Newman ME, Ben-Zeev A, Lerer B (1991) Chloroamphetamine did not prevent the effects of chronic antidepressants on 5-hydroxytryptamine inhibition of forskolin-stimulated adenylate cyclase in rat hippocampus. Eur J Pharmacol 12:207–213
Pandey SC, Isaac L, Davis JM, Pandey GN (1991) Similar effects of treatment with despramine and electroconvulsive shock on 5-hydroxytryptamine1A receptors in rat brain. Eur J Pharmacol 202:221–225
Papp M, Willner P, Muscat R (1991) An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology 104:255–259
Papp M, Lappas S, Muscat R, Willner P (1992) Attenuation of place preference conditioning but not place aversion conditioning by chronic mild stress. J Psychopharmacol 6:352–356
Peroutka SJ, Snyder SH (1980) Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding. Science 210:88–90
Robinson DS, Rickels KR, Feighner J, Fabre LF, Gammans RE, Shirotriya RC, Alms DR, Andary JJ, Messina ME (1990) Clinical effects of 5HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 10:67S-76S
Sampson D, Muscat R, Willner P (1991) Reversal of antidepressant action by dopamine antagonists in an animal model of depression. Psychopharmacology 104:491–495
Schweizer EE, Amsterdam JD, Rickels K, Kaplan M, Droba M (1986) Open trial of buspirone in the treatment of major depressive disorder. Psychopharmacol Bull 22:183–185
Sellinger-Barnette MD, Mendels J, Frazer A (1980) The effects of psychoactive drugs on beta-adrenergic binding sites in rat brain. Neuropharmacology 19:447–454
Schlegel JR, Peroutka SJ (1986) Nucleotide interactions with 5-HT1A binding sites directly labelled by [3H]-8-hydroxy-2-(di-n-propylamino)tetralin ([3H]-8-OH-DPAT). Biochem Pharmacol 35:1943–1949
Smith CE, Ware CJ, Cowen PJ (1991) Pindolol decreases prolactin and growth hormone responses to intravenousL-tryptophan. Psychopharmacology 103:140–142
Stamford JA, Muscat R, O'Connor JJ, Patel JJ, Wieczorek WJ, Kruk ZL, Willner P (1991) Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine. Psychopharmacology 105:275–282
Stanley M, Mann JJ (1983) Increased serotonin2 binding sites in frontal cortex of suicide victims. Lancet I:214–216
Vetulani J, Sulser F (1975) Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP generating system in limbic forebrain. Nature 257:495–496
Welner SA, De Montigny C, Desroches J, Desjardins P, Suranyi-Codotte BE (1989) Autoradiographic quantification of serotonin1A receptors in rat brain following antidepressant treatment. Synapse 4:347–352
Willner P (1984) The validity of animal models of depression. Psychopharmacology 83:1–16
Willner P (1985) Depression: a psychobiological synthesis. Wiley, New York
Willner P (1989) Sensitization to the actions of antidepressant drugs. In: Emmett-Oglesby MV, Goudie AJ (eds) Psychoactive drugs: tolerance and sensitization. Humana, Clifton, NJ, pp 407–459
Willner P (1990) Animal models of depression: an overview. Pharmacol Ther 45:425–455
Willner P, Towell A, Sampson D, Sophokleous S, Muscat R (1987) Reduction of sucrose preference by chronic mild stress and its restoration by a tricyclic antidepressant. Psychopharmacology 93:358–364
Willner P, Klimek V, Golembiowska K, Muscat R (1991) Changes in mesolimbic dopamine may explain stress-induced anhedonia. Psychobiology 19:79–84
Winer BJ (1971) Statistical principles in experimental design. McGraw Hill, London
Wise H, Halliday CA (1985) Why is amitriptyline much weaker than desipramine at decreasing beta-adrenoceptor numbers? Eur J Pharmacol 110:137–141
Yates M, Leake A, Candy JM, Fairbairn AF, McKeith IG, Ferrier IN (1990) 5HT2 receptor changes in major depression. Biol Psychiatry 27:489–496
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Papp, M., Klimek, V. & Willner, P. Effects of imipramine on serotonergic and beta-adrenergic receptor binding in a realistic animal model of depression. Psychopharmacology 114, 309–314 (1994). https://doi.org/10.1007/BF02244853
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02244853